JPMorgan Chase & Co. Buys 28,606 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO)

JPMorgan Chase & Co. boosted its stake in Abeona Therapeutics Inc (NASDAQ:ABEO) by 74.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 67,138 shares of the biopharmaceutical company’s stock after purchasing an additional 28,606 shares during the quarter. JPMorgan Chase & Co.’s holdings in Abeona Therapeutics were worth $424,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in ABEO. Jane Street Group LLC acquired a new position in shares of Abeona Therapeutics in the 3rd quarter valued at $84,000. Charles Schwab Investment Management Inc. bought a new position in Abeona Therapeutics during the third quarter worth about $151,000. XTX Topco Ltd acquired a new position in Abeona Therapeutics in the third quarter valued at about $160,000. GSA Capital Partners LLP grew its stake in Abeona Therapeutics by 54.3% in the third quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock valued at $607,000 after acquiring an additional 33,831 shares during the period. Finally, abrdn plc increased its holdings in shares of Abeona Therapeutics by 158.8% in the third quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock worth $2,067,000 after acquiring an additional 200,647 shares in the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Stock Up 0.7 %

Shares of Abeona Therapeutics stock opened at $5.45 on Thursday. The firm has a market cap of $236.92 million, a PE ratio of -2.03 and a beta of 1.46. The business’s 50 day simple moving average is $5.74 and its 200 day simple moving average is $5.73. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. Abeona Therapeutics Inc has a 52-week low of $3.05 and a 52-week high of $9.01.

Analyst Upgrades and Downgrades

ABEO has been the subject of several research analyst reports. StockNews.com lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 9th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a report on Monday, November 25th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $18.00 price objective on shares of Abeona Therapeutics in a report on Tuesday, October 29th.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.